That is necessary, due to the fact that the way a protein in the human body folds figures out if a pharmaceutical will have the ability to bind to that protein and be efficient. In other words, we need to understand how these proteins fold if we want a drug to work. Historically, this has actually been a trial-and-error procedure (future report). And now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it much easier to produce drugs that do what they're designed to do. This was a development almost nobody observed. However it's going to have profound ramifications for treating disease. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, of course, there will be lots of financial investment opportunities in this area, too. Moving topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (biotech stocks). That said, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be amazed if it drew back maybe considerably before going higher - genetic sequencing companies jeff brown. I have actually been covering bitcoin for a very long time now. Among the very first research reports I ever released was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial recommendation, I entitled my report "What's the Big Deal With Bitcoin?" That shows you where the conversation was at the time. We were primarily educating readers. But that's not the big question any longer. Now we're seeing institutional cash lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. Mass, Mutual is a trusted 170-year-old organization. So think about that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a big factor I'm bullish on it this year. bleeding edge. Regards, Jeff Brown, Editor, The Bleeding Edge I have a reward forecast 2020 was a record year for IPOs. 552 U.S. business went public the most in more than twenty years. These companies raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I predict 2021 will be another record year in IPOs. There are a lot of fantastic private business on the edge of hitting the general public markets And I've been working on a new way for you to invest even before these companies go public.
This opportunity has been developing over the last couple of years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover all the details. Go right here to schedule your spot free of charge.
Emma Walsh here, handling editor of the Journal. Regular Diary readers understand that tech isn't our typical beat (the legacy report predictions). And when it concerns tech investing, we leave it to the specialists. Fortunately, we have numerous such experts in our Rolodex. Our associate Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing professionals we understand (jeff brown prediction for 2021). In truth, he had a number of triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take a look at the huge picture and anticipate what's just around the corner.
That includes things like 5G networks, biotech, expert system, and much more. These patterns are experiencing exponential growth and producing extraordinary chances for financiers. I wish to make sure all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see coming in the next 12 months Our brand-new 5G (fifth-generation) wireless networks are a subject I've been covering for years now. jeff bezos. But despite what lots of readers might think, this is a trend that's just beginning. Despite the fact that the COVID-19 pandemic interfered with supply chains in 2015, an impressive 250 million 5G-enabled devices were still sold.
And all of this ultimately resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (biotech stock). Losing two months of production and sales really affects the number of 5G devices are offered in the fiscal year. When you think about all of that, selling 250 million units is remarkable. More notably, the hold-ups triggered by the pandemic developed a lot of bottled-up demand. Which need is now going to be pushed into 2021. In truth, I forecast that more than 500 million 5G gadgets will be shipped in 2021 - white house. And that's not my only 5G forecast When I have actually spoken about 5G in the past, I've explained its 3 different stages.
In Stage 2, 5G devices go on sale. 5G phones and other items begin to reach customers. And in Stage Three, 5G services start to be provided (self-driving cars). That's when we begin to see applications running on 5G networks. Consider things like huge multiplayer games over a cellphone. That's not possible with 4G. It will be with 5G. And my 2nd 5G forecast for 2021 is that we will begin Stage 3 by this summertime. This starts something of a virtuous cycle: The majority of individuals do not actually care about the innovation. But they will care if there are amazing applications that can just be accessed with a 5G phone.
That results in more 5G apps being developed. In reality, 5G is going to open a suite of incredible applications: self-driving cars and trucks, the Internet of Things, robotic surgical treatment, and more. All of these technologies require 5G. The investment opportunities going forward will be massive. Stepping far from 5G, the next important innovation I predict in 2021 is CRISPR genetic editing. CRISPR means "clustered routinely interspaced brief palindromic repeat." It's a mouthful. However it's one of the most exciting developments in biotechnology. At a high level, CRISPR is a technology that can edit our genetic makeup as if it were software.
The program can crash or not function correctly. CRISPR utilizes a similar concept but with our genetic code. "Typos" in our genome can result in disease. CRISPR can fix these "typos." For several years, CRISPR was primarily a niche innovation that wasn't well understood. And during that time, there were truly only 3 business operating in this area. However things are changing. CRISPR is no longer simply theoretical. We're seeing actual outcomes. We're treating illness and seeing that this innovation simply works. And as an outcome, a "2nd crop" of early-stage CRISPR business is going public and providing unbelievable returns. This entire industry is efficiently a greenfield chance.
There's room for lots of companies to exist in this area. brownstone research. And there will be more. That's my prediction for CRISPR in 2021. I anticipate that two or 3 more hereditary editing business will hold their IPOs. Sticking to biotechnology, we are seeing amazing things taking place at the convergence of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, simply announced at the end of 2020 that its most current Alpha, Fold software can properly anticipate the folding of a protein based solely on its amino acid series with 92. 4% precision. That's important because the way a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and be reliable.
Historically, this has been an experimental process. Today, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it much simpler to develop drugs that do what they're developed to do. And here's my next forecast. I forecast that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not simply one however a number of drug treatments produced using this innovation. This was among those breakthroughs that practically nobody observed. However it's going to have profound implications for curing illness. And, of course, there will be lots of investment chances in this space, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be volatile. We're close to all-time highs. I would not be shocked if it pulled back possibly significantly before going greater. I have actually been covering bitcoin for a long time now. Among the first research study reports I ever published was on bitcoin - genetic sequencer stock jeff brown. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ roi for any person who followed my recommendation. However at the time of that preliminary recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
However no one is asking that concern anymore. Now, we're seeing institutional cash lastly taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche business. jeff bezos. Mass, Mutual is a 150-year-old organization. So think about that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another bonus offer forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and claims the information depends on date since February 2021, but we could not individually validate this claim. Given Jeff Brown's past, he likely has a substantial net worth, but we can't hammer down a precise figure at this minute. Brown is best understood for his sage-like capability to pick winning technology stocks. He invested more than 25 years looking into innovation companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience provides him an outstanding point of view on the market. He's constantly on the hunt for brand-new chances, and he shares much of his finest choices in the Near Future Report.
That's full marks, but it's not ridiculously reasoned. Brown has an excellent reputation as a stock-picker, and he effectively forecasted some of the most significant financial occasions of the past 20 years. Although he doesn't appear to launch his choices to the general public, the service's success is a direct indicator of Brown's stock-picking prowess. Nobody on Wall Street gets it best whenever, but Jeff Brown's precise forecasts have earned him legions of dedicated fans. That states a lot about his ability. The Future Report is published by Brownstone Research, a popular monetary research study publisher. Brownstone Research study uses numerous research study services with a wide range of specializations - jeff brown 1 biotech company.
The company is likewise affiliated with Bonner & Partners, another well-respected research publisher - brownstone research. On its site, Brownstone says its mission is to provide retail investors with professional-grade research: "For too long, the very best financial investment research has not been readily available to specific financiers. It has been normally scheduled for financial investment banks, hedge funds, private equity, and high-net-worth clients. jeff brown stock predictions. The objective of Brownstone Research is to make that type of proprietary research study readily available to any financiers seeking to gain an edge in the marketplaces. The objective is easy to provide unique and successful investment research study found nowhere else." -Brownstone Research site excerpt from the Jeff Brown is the founder of Brownstone Research study, and he also functions as the firm's Chief Financial investment Analyst.
With Brown guiding the ship, Brownstone Research study is a powerhouse publisher with lots to use its clients. After years of stable success at the helm of top-tier business like Tesla and Area, X, Elon Musk is a home name throughout many of America. If you understand even a little bit about the marketplace, you know that he has a track record as a King Midas of sorts. the legacy report predictions. Whatever he touches turns to gold! Jeff is aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge task.
In truth, Brown believes S.A.V. jeff brown biotech stocks. might be "the most significant trend of the 2020s, and he's not alone. Take a look at these quotes from other well-known S.A.V. bulls: Elon's next big act will be marrying two advanced technologies: expert system and electric automobiles. Musk hopes the mix will assist him develop the first fully-autonomous, self-driving cars ever. It's nothing brief of the automobile market's Holy Grail. As you know, electrical lorries and self-driving automobile stocks have actually been big this year, however the Wall Street device has been big on buzz without much tangible result. Despite a drastic boost in competition over the previous couple of years, Brown still thinks Musk has the finest chance of putting everything together.
tech might be the magic string that connects all of it together. S.A.V. means Shared Autonomous Automobile, and it could be the future of transportation. Basically, this technology would enable you to lease your vehicle as an autonomous, self-driving taxi when you're not utilizing it. You just leave the vehicle and press a button on an app that tells the vehicle to "sign up with the fleet." Next thing you know, you're unwinding on your sofa while your car shuttles ride-sharers around town. Best of all, you get to keep a substantial piece of the profits. It sounds insane, however it could be closed than you think.